Cerevel Therapeutics Holdings Inc expected to post a loss of 64 cents a share - Earnings Preview

Cerevel Therapeutics Holdings

20/02/2023 14:40

* Cerevel Therapeutics Holdings Inc  CERE.OQ   CERE.O  is
expected
to show no change in quarterly revenue when it reports 
results on February 22. 
    * 
    * ​Refinitiv's mean analyst estimate for Cerevel
Therapeutics
Holdings Inc is for a loss of 64 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cerevel
Therapeutics Holdings Inc is $40​, above​ its last closing price
of $33.59. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.62       -0.62      -0.66     Missed  -7.1
 Jun. 30 2022  -0.50       -0.48      -0.62     Missed  -30.3
 Mar. 31 2022  -0.43       -0.42      -0.46     Missed  -8.2​
 Dec. 31 2021  -0.41       -0.41      -0.40     Beat    1.6
 ​​Sep.        -0.36       -0.40      -0.43     Missed  -8.4
 30 2021                                                
 Jun. 30 2021  -0.40       -0.39      -0.42     Missed  -7​
 Mar. 31 2021  -0.43       -0.41      -0.40     Beat    3.2
 Dec. 31 2020  -0.62       -0.45      -0.27     Beat    40
 This summary was machine generated February 20 at 14:40 GMT. 
All figures in US dollars  unless otherwise stated